Table 3.
Associations between somatic mutations in tumour samples and survival.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Hazard ratio (95% confidence interval) | p value | Hazard ratio (95% confidence interval) | p value | |
| High TMB (>20/Mb) | 0.56 (0.43–0.72) | 1.64 × 10–6*** | 0.75 (0.57–1.01) | 0.051 |
| High MSI (>15%) | 0.58 (0.45–0.76) | 1.62 × 10–5*** | 0.80 (0.59–1.07) | 0.13 |
| TP53 mutation | 1.31 (1.11–1.54) | 9.59 × 10–4* | 1.12 (0.94–1.35) | 0.20 |
| KRAS mutation (driver) | 1.17 (1.01–1.36) | 0.037 | Not included | |
| BRAF mutation | 1.42 (1.16–1.74) | 9.50 × 10–4* | 1.16 (0.92–1.45) | 0.21 |
| APC mutation | 0.84 (0.71–1.00) | 0.053 | Not included | |
Univariate associations between somatic mutations in tumor samples and survival (left). Multivariate associations for each somatic mutation after adjusting for age at diagnosis, year of diagnosis, stage, location and tumour pathology (right). p Values are results from likelihood ratio tests. For the univariate analysis, statistical significance is indicated with * for p values <8.4 × 10–3, ** for p values <8.4 × 10–4 and *** for p values <8.4 × 10–5 after adjustment for the number of hypothesis (6). For the multivariate analysis, statistical significance is indicated with * for p values <5 × 10–2, ** for p values <5 × 10–3 and *** for p values <5 × 10–4.